MannKind's inhaled insulin Afrezza hit with US FDA complete response letter
This article was originally published in Scrip
Shares in the US company MannKind dropped by 25% earlier this week as investors reacted to a US FDA complete response letter for its inhaled rapid-acting insulin product Afrezza (formerly Afresa).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.